COYA Key Statistics, Chart & Performance
The current stock price of COYA is 4.85 USD. In the past month the price decreased by -20.36%. In the past year, price decreased by -15.94%.
COYA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About COYA
Company Profile
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The firm's 300 Series product candidates include COYA 301 and COYA 302.
Company Info
COYA THERAPEUTICS INC
5850 San Felipe St., Suite 500
Houston TEXAS US
Employees: 8
Phone: 8005878170
COYA THERAPEUTICS INC / COYA FAQ
What does COYA do?
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The firm's 300 Series product candidates include COYA 301 and COYA 302.
Can you provide the latest stock price for COYA THERAPEUTICS INC?
The current stock price of COYA is 4.85 USD. The price decreased by -5.27% in the last trading session.
Does COYA stock pay dividends?
COYA does not pay a dividend.
How is the ChartMill rating for COYA THERAPEUTICS INC?
COYA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for COYA THERAPEUTICS INC?
COYA THERAPEUTICS INC (COYA) currently has 8 employees.
Can you provide the upcoming earnings date for COYA THERAPEUTICS INC?
COYA THERAPEUTICS INC (COYA) will report earnings on 2026-03-16, before the market open.
What is the outstanding short interest for COYA THERAPEUTICS INC?
The outstanding short interest for COYA THERAPEUTICS INC (COYA) is 2.72% of its float.
COYA Technical Analysis
COYA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to COYA. While COYA has a great health rating, there are worries on its profitability.
COYA Financial Highlights
Over the last trailing twelve months COYA reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS decreased by -111.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.53% | ||
| ROE | -67.56% | ||
| Debt/Equity | 0 |
COYA Forecast & Estimates
13 analysts have analysed COYA and the average price target is 16.39 USD. This implies a price increase of 238% is expected in the next year compared to the current price of 4.85.
For the next year, analysts expect an EPS growth of -26.34% and a revenue growth 64.44% for COYA